

1 Association between kidney measurements and 2 cognitive performance in patients with ischemic stroke

3 Running title: Kidney measures and Cognitive Function

4

5 Author name: Chunyan Zhang¹, Guofang Xue¹, Yanjuan Hou², Pengfei Meng¹,

6 Huizhong Gao¹, Bo Bai¹, Dongfang Li¹

7

8 ¹Author affiliations: Department of Neurology, Second Hospital, Shanxi Medical

9 University, 382 Wuyi Road, Taiyuan, Shanxi, China;

10 ²Author affiliations: Department of Nephrology, Second Hospital, Shanxi Medical

11 University, 382 Wuyi Road, Taiyuan, Shanxi, China.

12 *Correspondence: Chunyan Zhang

13 Address: Second Hospital, Shanxi Medical University, 382 Wuyi Road, Taiyuan, Shanxi,

14 China;

15 Email: marzipanzcy@126.com

16

17

18

19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 **Abstract**

21 **Background** Relationships between low estimated glomerular filtration rate (eGFR)
22 and albuminuria with poorer cognitive performance in patients with ischemic stroke
23 are less clear. Our aim was to retrospectively ascertain the associations between
24 these renal measures and cognitive performance in patients with ischemic stroke.

25 **Methods** Retrospective analysis was performed on 608 patients with acute
26 ischemic stroke. Urine albumin-creatinine ratio (UACR) and eGFR were obtained
27 from inpatient medical records. Global cognitive function via mini-mental state exam
28 (MMSE) and Montreal Cognitive Assessment (MoCA) was determined one month
29 after hospital discharge. The relationship between renal measures and cognitive
30 performance was assessed using univariate and multiple linear regression analyses.

31 **Results** Patients had an average age of 66.6 ± 4.1 years, and 48% were females.
32 Average eGFR and UACR were 88.4 ± 12.9 ml/min/1.73m² and 83.6 ± 314.2 mg/g,
33 respectively. The number of patients with an eGFR of ≥ 90 , 60 to 89, and < 60
34 ml/min/1.73 m² were (371, 61%), (207, 34%) and (30, 5%) respectively. The
35 proportions with a UACR < 30 mg/g, 30-300mg/g and > 300 mg/g were 56%, 39% and
36 5%. Multivariate adjusted models showed that eGFR was independently associated
37 with MMSE ($\beta = -0.4$; 95% CI= -0.5,-0.4; $p < 0.001$) and MoCA ($\beta = -0.6$; 95% CI= -0.7,-
38 0.5; $p < 0.001$). However, the correlations between UACR and MMSE and MoCA were

39 statistically non-significant.

40 **Conclusion** In patients with ischemic stroke, reduced eGFR but not albuminuria
41 was associated with lower cognitive performance. These results show that the eGFR
42 decline could be an effective indicator of cognitive impairment after a stroke.
43 Therefore, regular monitoring and early detection of mild renal dysfunction in
44 patients with acute ischemic stroke might be needed.

45 **Keywords:** cognitive performance, elderly, estimated glomerular filtration rate,
46 urine albumin-to-creatinine ratio, ischemic stroke

47

48

49

50

51

52

53

54

55

56

57

58 **Introduction**

59 Globally, cognitive impairment is a major health problem during old age. Due to
60 better living conditions and healthcare, humans have extended lifespans, and this
61 has led to a rapid increase in the prevalence of cognitive dysfunction disorders.(1)
62 The identification of modifiable risk factors of cognitive decline or dementia is of
63 vital importance in developing preventive strategies.(2) Chronic kidney disease (CKD)
64 is a global health burden with a high economic cost to health systems. CKD is defined
65 by indicators of renal dysfunction, such as estimated glomerular filtration rate
66 (eGFR), and kidney damage, such as urine albumin-creatinine ratio (UACR).(3)
67 Numerous cross-sectional or longitudinal studies have been performed to explore
68 the relationship between kidney disease and cognitive dysfunction, but the available
69 data are conflicting.(4-15)
70 A recent study on the Northern Ireland Cohort for the Longitudinal Study of Ageing
71 (NICOLA) revealed that decreased eGFR had a significant association with an
72 increased risk of cognitive dysfunction in a cohort of older adults.(16) The Maastricht
73 Study found albuminuria but not eGFR to be independently associated with cognitive
74 impairment, specifically within the domain of information processing speed.
75 However, both albuminuria and eGFR were more significantly associated with
76 cognitive impairment in older individuals.(6) A prospective study in a Chinese

77 population aged 80 years and more found early-stage CKD to have a correlation with
78 cognitive decline.(17) Palmer et al found that in the African-American population
79 with type 2 diabetes (T2D), eGFR and albuminuria were associated with cognitive
80 dysfunction, even in mild kidney disease.(18) Cognitive impairment was found to
81 occur early in CKD.(19) However, Helmer et al did not find an increased risk of
82 cognitive decline or dementia to be associated with low eGFR level. Rather, they
83 found that a faster decline in eGFR and proteinuria was associated with incidence of
84 cognitive impairment and dementia with a vascular component.(20)

85 The incidence of cognitive impairment after cerebrovascular accidents (CVA) in China
86 is as high as 80.9%, including 48.91% for cognitive impairment without dementia and
87 32.05% for cognitive impairment with dementia.(21) Patients with CVA are at a high
88 risk of suffering cognitive dysfunction. CVA increased the relative risk of dementia by
89 3.7-fold to 6.6-fold in older adults aged 61–74 years, and advanced the onset of
90 dementia by nearly 10 years.(22) However, few studies have examined whether the
91 association between low eGFR and albuminuria with poorer cognitive performance
92 are limited to individuals with high-risk factors or patients with stroke. A longitudinal
93 study found that CKD was independently related to incident dementia in patients
94 with vascular risk factors and partly support a role for common vascular mechanisms
95 as the underlying pathophysiology of AD dementia.(23) Recently, a study in patients

96 with TIA and stroke found CKD was not independently associated with either pre- or
97 post-event dementia, suggesting that renal-specific mechanisms are unlikely to play
98 an important role in aetiology.(24)
99 This study aimed to investigate whether low eGFR and albuminuria, measured by
100 UACR, are independently and/or jointly associated with worse cognitive
101 performance in patients with ischemic stroke.

102

103 **Materials and Methods**

104 **Data source**

105 Using a retrospective design, this study analyzed data from 608 patients aged 60 to
106 80 years with acute ischemic stroke within 72 hours of onset between January 2016
107 and December 2020 from inpatient medical records and a database of cognitive
108 assessment results for outpatient visits one month after hospital discharge. Data was
109 collected from September 1, 2019. During or after data collection, investigators had
110 access to information that could identify individual patients. All patients were no
111 history of a cognitive disorder before stroke and were able to complete the
112 assessment, excluding patients who could not cooperate with the examination, such
113 as aphasia or consciousness disorder. The study was conducted at the Department of
114 Neurology, Second Hospital of Shanxi Medical University, Taiyuan, a tertiary hospital

115 in Shanxi, China. This study was approved by the Ethics Committee of the Second
116 Hospital of Shanxi Medical University (NO. 2019YX214) . The research was
117 completed in accordance with Helsinki Declaration. Due to the retrospective nature
118 of the study, informed consent of the patients was not required. The data included
119 renal function parameters, such as serum creatinine and UACR, and cognitive
120 function test findings, such as mini-mental status examination (MMSE) and Montreal
121 Cognitive Assessment (MoCA) scores.

122 **Clinical and laboratory data**

123 Clinical data extracted from hospital records on admission, included systolic and
124 diastolic blood pressure on admission, self-reported demographic characteristics
125 (age, gender, height, weight, years of education, smoking and alcohol consumption
126 status, and diabetes mellitus and hypertension history), laboratory results (total
127 cholesterol, triglyceride, homocysteine, uric acid, fasting glucose, urea, creatinine,
128 and UACR). Additionally, data on neural function assessment (National Institutes of
129 Health Stroke Scale [NIHSS] score) were available. All patients were diagnosed as
130 large artery atherosclerosis (LAA), cardioembolism (CE), small artery occlusion (SAO),
131 stroke of other determined cause (SOC), and stroke of undetermined cause (SUC)
132 according to TOAST classification.(25) Body mass index (BMI) was calculated as
133 weight (in kilograms) divided by height (in meters) squared. eGFR was calculated
134 using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation,
135 which is more accurate than the modification of diet in renal disease (MDRD)
136 equation.(26)

137
$$eGFR=141\times\min(Scr/k,1)^\alpha\times\max(Scr/k,1)^{-1.209}\times0.993^{age}\times1.018[\text{if female}]$$

138 Where serum creatinine (Scr) is expressed in mg/dL and age in years; κ is 0.7 for
139 females and 0.9 for males; α is -0.329 for females and -0.411 for males; min
140 indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.

141 **Cognitive impairment testing**

142 All the cognitive function tests were assessed by two neuropsychological assessors
143 trained in consistency using MMSE and MoCA one month after hospital discharge.
144 The MMSE and MoCA scores ranged from 0 to 30; higher scores indicated better
145 cognitive function. MMSE testing components included 30 point within four
146 dimensions: ten points for orientation, six for registration and memory, five for
147 attention and calculation, and nine for language and visuospatial abilities. MoCA
148 testing domains included visuospatial and executive function (5 points), naming (3
149 points), memory (5 points), attention (6 points), language/abstraction (5 points) and
150 orientation (6 points).

151 **Statistical analysis**

152 The study was based on analysis of data obtained from a retrospective design.
153 Patient characteristics were presented as means \pm standard deviations (SD) for
154 continuous variables, and categorical variables were reported as frequencies and
155 percentages. Differences between groups for continuous data were tested by one-

156 way analysis of variance (ANOVA). Differences between groups for proportions were
157 tested with a Chi-square test. Data on UACR were not normally distributed;
158 therefore, they were log-transformed before analysis. Standard definitions were
159 used to categorize eGFR data into three groups, comprising ≥ 90 ml/min/1.73 m² as
160 reference, 60–89 ml/min/1.73 m², and < 60 ml/min/1.73 m². Thereafter, eGFR was
161 analyzed as a continuous variable (per 5 mL/min/1.73 m² decreased). UACR values
162 were categorized as < 30 mg albumin/g creatinine (normal to mildly increased as
163 reference), 30–300 mg/g (moderately increased), and > 300 mg/g (severely
164 increased). Multivariate linear regression was used to assess the association
165 between eGFR or UACR and cognitive performance, with eGFR or UACR as the
166 independent variable and MoCA and MMSE scores as the dependent variables. Two
167 models, Models 1 and 2, were used for the regression analysis. Model 1 was crude,
168 and multivariate-adjusted Model 2 was constructed to adjust for potential
169 confounding variables associated with kidney function and/or cognitive function,
170 including age, gender, BMI, education, diabetes and hypertension history, NIHSS
171 score, stroke subtypes, smoking and alcohol consumption status, serum total
172 cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood
173 pressure (SBP), and either eGFR or UACR. Crude and adjusted β with 95% CIs are
174 presented. Two-tailed $P < 0.05$ was considered statistically significant. All analyses

175 were performed using Empower (R)(www.empowerstats.com, X&Y Solutions Inc.,
176 Boston, MA) and R (<http://www.R-project.org>).

177

178 **Results**

179 **Population characteristics**

180 Table 1 shows demographic and laboratory data on all 608 patients. Patients had a
181 mean age of 66.6 years (SD: 4.1 years) and 48% of patients were females. Average
182 eGFR and UACR were 88.4 ± 12.9 ml/min/1.73 m² and 83.6 ± 314.2 mg/g, respectively.

183 Levels of eGFR were >90 ml/min/1.73m² (N=371, 61%), $60-89$ ml/min/1.73m²
184 (N=207, 34%), and <60 ml/min/1.73m² (N=30, 5%). The number of patients with
185 UACR <30 mg/g was 338 (56%). Moderately increased UACR, defined as a UACR 30-
186 300mg/g, was present in 240(39%) of patients, and severely increased UACR, defined
187 as a UACR >300 mg/g, was present in 30(5%) of patients.

188 Patients with lower eGFR categories were more likely to be older and former or
189 current alcohol consumers and smokers. In addition, they were more likely to have
190 diabetes mellitus, and hypertensive disease, and high systolic blood pressure (SBP)
191 and diastolic blood pressure (DBP) on admission. Their homocysteine, blood glucose,
192 uric acid, and total cholesterol levels were more likely to be higher, as well as a
193 higher BMI. The eGFR levels were lower in patients with albuminuria than in normal

194 patients. As compared with patients with UACR <30 mg/g, patients with UACR ≥30
195 mg/g were more likely to be living with obesity, diabetes mellitus, and hypertensive
196 disease. Additionally, they were more likely to have higher SBP and DBP, blood
197 glucose, uric acid, and homocysteine levels. Patients had lower cognitive scores in
198 the lower eGFR and higher UACR categories (Table 1).

199 **Independent and combined associations between eGFR and** 200 **UACR levels and cognitive performance**

201 Table 2 contains the results of unadjusted and fully adjusted (age, gender, BMI,
202 education, diabetes and hypertension history, NIHSS score, stroke subtypes ,
203 smoking and alcohol consumption status, serum total cholesterol, triglyceride, uric
204 acid, homocysteine, fasting glucose, SBP, and eGFR or UACR) models for continuous
205 and categorical relationships between measures of renal disease and cognitive tests.
206 The correlation between UACR and MMSE and MoCA scores in crude and
207 multivariate adjustment were statistically non-significant. In the crude and adjusted
208 analyses, no independent associations were observed between UACR, as a category,
209 and cognitive performance. Similarly, no independent associations were observed
210 when UACR was analyzed as a continuous variable in Models 1 and 2 (Table 2).
211 The association between eGFR and the tests of cognitive performance was evaluated
212 with crude and multivariable linear regression analyses. eGFR was analyzed as a

213 categorical (≥ 90 , 60-90, and < 60 ml/min/1.73 m²) and a continuous (per 5
214 ml/min/1.73 m² decrease) variable. In the multivariable adjustment model, for
215 patients with eGFR 60–90 ml/min/1.73 m² compared to patients with eGFR ≥ 90
216 ml/min/1.73 m², an association existed between eGFR and MMSE (β , -0.7; 95%CI, -
217 1.0 to -0.3) and MoCA (β , -1.4; 95%CI, -1.7 to -1.0). The association between eGFR
218 < 60 ml/min/1.73 m² and cognitive performance was stronger. In the multivariable
219 adjustment model, MMSE and MoCA were (β , -4.2; 95%CI -5.0, -3.4) and (β , -5.2;
220 95%CI -6.1, -4.4), respectively. When examined as a continuous variable (per 5
221 ml/min/1.73 m² decrease) in crude and fully adjusted models, eGFR decrements
222 were positively associated with lower MMSE and MoCA scores ($p < 0.001$) (Table 2). In
223 all cases, lower levels of eGFR were associated with poorer cognitive performance.
224 To assess generalizability, a fully adjusted regression model was created for
225 analyzing the subgroups of sex, stroke subtypes, age, SBP, NIHSS, and blood glucose
226 levels. The results were similar in the subgroup analyses. No significant interactions
227 were found among any of the stratified variables (male versus female, large artery
228 versus small vessel occlusion, age, SBP, NIHSS, and blood glucose dichotomized
229 group: higher versus lower) with eGFR or UACR for cognitive testing. (Tables 3 and 4)
230 When combined categories of eGFR (< 90 and ≥ 90 ml/min/1.73 m²) and albuminuria
231 (< 30 and ≥ 30 mg/g) were analyzed, the MMSE and MoCA scores were the least in

232 those patients with UACR ≥ 30 mg/g and eGFR < 90 ml/min/1.73 m², compared to
233 those without albuminuria and eGFR level of ≥ 90 ml/min/1.73 m² in the crude and
234 fully adjusted model (Table 5).

235

236 **Discussion**

237 This study found that in old adults with ischemic stroke in China, reduced eGFR, but
238 not albuminuria measured by UACR, has an independent association with poorer
239 cognitive performance. This study supports findings from prior studies reporting a
240 link between kidney function and cognitive impairment.

241 **eGFR and cognitive performance**

242 Our results showed that, in the absence or presence of albuminuria, an eGFR < 90
243 ml/min/1.73 m² had an association with worse cognitive performance. However, the
244 presence of albuminuria amplified the relationship. These findings corroborate the
245 findings of prior studies on the association between renal measures and poorer
246 cognitive performance. According to previous reports, this association exists during
247 the early stages of renal dysfunction.(17, 18) The association between renal function
248 and cognitive performance has been paid much attention in recent decades. Wang
249 et al found that both CKD and eGFR were associated with cognitive dysfunction
250 among older patients with hypertension in China.(27) A prospective study

251 demonstrated that kidney dysfunction is associated with a cognitive decline in a
252 community-based population, and this association is independent of
253 albuminuria.(28) Another longitudinal study suggested that a low eGFR was
254 associated with increased risk of dementia. In addition, a faster decrease in eGFR
255 and proteinuria was associated with incidence of cognitive impairment and
256 dementia; this association may be mediated by vascular mechanisms.(20)
257 Additionally, a large population study found that each 10 ml/min/1.73 m² decrease
258 in eGFR<60 ml/min/1.73 m² was independently associated with an increased
259 prevalence of cognitive impairment.(29) The OSACA2 study found that CKD was
260 independently related to incident dementia in patients with vascular risk factors.(23)
261 However, one cohort study from the Oxford Vascular Study (OXVASC) did not find
262 CKD was associated with either pre- or postevent dementia in patients with TIA and
263 stroke.(24) The inconsistent results may be attributable to different study
264 populations and severity of lesion. OXVASC has focused on the relationship between
265 CKD and dementia in the patients with TIA and stroke. Participants in SPRINT were in
266 older community-dwelling adults with cardiovascular disease. OSACA2 was in high-
267 risk patients for the primary and secondary prevention of cardiovascular disease.
268 Another potential reason is different methods of assessment. Many previous studies
269 have used different assessment tools to evaluate cognitive function.

270 Although the precise pathophysiologic mechanisms that underlie the association
271 between low eGFR and poorer cognitive performance are not known and need
272 further studies for clarity, several factors may help explain the association between
273 low eGFR and cognitive dysfunction. Patients with renal dysfunction have a higher
274 prevalence of cerebrovascular disease (CVD) than the general population. Renal
275 dysfunction may contribute to vascular cognitive impairment through traditional
276 CVD risk factors, including hypertension, diabetes mellitus, dyslipidemia, smoking,
277 and other non-traditional vascular risk factors comprising hyperhomocysteinemia,
278 hyperuricemia, anemia, inflammation, and oxidative stress. Moreover, CKD
279 characterized by the accumulation of uremic toxins, excessive RAS activation, renal
280 anemia, and renal osteopathy, caused by renal dysfunction are possible mechanisms
281 of renal disease involvement in the progression of dementia.(30, 31) Conceptually,
282 low eGFR may lead to the accumulation of neurotoxins or may represent a
283 prolonged exposure to CVD or its risk factors.(6) Vascular dementia is often linked to
284 hypertension, which is a common finding in CKD. Hypertension has often been
285 associated with small lacunar infarcts and leukoaraiosis, cerebral autoregulation
286 dysfunction, and chronic hypoperfusion. Although cerebral blood flow may be
287 adequate in CKD, the blood–brain barrier or the glymphatic system might be
288 dysfunctional. In this study, more than 50% of the patients had hypertension. Uremic

289 toxins in circulation, which enter the central nervous system (CNS) as a result of
290 blood-brain barrier damage during kidney dysfunction, might impair CNS structure
291 and function.(32)

292 **Albuminuria and cognitive performance**

293 According to recent systematic review and meta-analysis studies, albuminuria has a
294 significant association with cognitive impairment and dementia.(4, 33, 34) To the
295 best of our knowledge, albuminuria is a significant risk factor for the development of
296 dementia in community-based Japanese older adults. Moreover, low eGFR and
297 albuminuria are mutually associated with a greater risk of vascular dementia.(35) A
298 prospective cohort study demonstrated that persistent or progressive albuminuria is
299 associated with cognitive decline in adults with diabetes and normal eGFR.(36) Wei
300 et al found that urine albumin is significantly associated with cognitive dysfunction,
301 and can be potentially used as an early marker for CKD.(37)

302 The mechanism underlying the association between albuminuria and poorer
303 cognition is not completely understood and is likely multifactorial. Both cerebral and
304 renal circulations have high flow and low impedance. The association between
305 albuminuria and cognitive impairment probably reflects common microvascular
306 pathogenesis in the kidneys and brain. Several reasons may explain the
307 inconsistencies between our findings and those of previous reports. First, the

308 conflicting results may be attributable to use of different study populations in
309 studying the severity of albuminuria. Patients with cognitive dysfunction may reflect
310 in another chronic microvascular disease. This may explain why dementia and poorer
311 cognitive performance are more common in individuals with diabetes who have a
312 high prevalence of albuminuria.(36, 38) However, since fewer patients with diabetes
313 participated in this study (8%), these findings should be interpreted with caution.
314 The study might be underpowered to detect the association between UACR and
315 poorer cognitive performance. Second, this study only measured UACR at a single
316 time point. UACR is affected by exercise and the time of day the sample is taken,(39)
317 which is why repeated measurements would be preferred. The true association
318 between albuminuria and cognitive performance is likely to be diluted. An
319 alternative explanation for the disparate results of the association between low
320 eGFR and albuminuria and poorer cognitive performance could be that albuminuria
321 is a marker for a different condition other than kidney disease.(40)
322 This study had several strengths. First, the primary independent and dependent
323 variables were quantified using clinically relevant measures (eGFR and UACR for two
324 independent markers of renal function and damage and MoCA and MMSE for
325 cognitive performance), thus providing clinical relevance to the analyses. In addition,
326 the use of both eGFR and UACR as correlators enabled us to test their independent

327 and joint effects on cognitive performance. Second, the study controlled for several
328 potential confounders, including demographic and clinical parameters, while
329 assessing the association.

330 Several limitations were noted. First, our study population contained a small number
331 of patients with CKD (eGFR <60 ml/min/1.73 m²), which limited our ability to detect
332 a relationship between eGFR <60 ml/min/1.73 m² and cognitive performance.

333 Second, these parameters were based on a one-time evaluation and do not provide
334 information on the duration or severity of risk factors over time. Third, we did not
335 analyze impairment in specific cognitive domains; instead, overall cognitive scores
336 were used in the analysis. Finally, the cognitive assessment was performed one
337 month after hospital discharge, and the incidence of post-stroke cognitive
338 impairment is highest three months after stroke.⁽⁴¹⁾ Further long-term follow-up is
339 still needed.

340 Our findings support the hypothesis that renal dysfunction and albuminuria may
341 operate through different pathophysiologic mechanisms. They further suggest that
342 the pathways mediating the association between low eGFR and albuminuria and
343 poorer cognitive performance may be partially distinct. The findings have clinical
344 implications. Our results suggest that the measurement of eGFR is a good biomarker
345 for cognitive impairment in patients with acute ischemic stroke. Low eGFR may

346 reflect a partially distinct pathophysiologic process of cognitive dysfunction.
347 Targeting the pathogenesis of low eGFR or treating modifiable risk factors may have
348 clinical implications in preventing cognitive impairment or delaying disease
349 progression. Further studies are needed to confirm whether the setting of kidney
350 dysfunction is a possible new determinant for cognitive impairment in patients with
351 stroke.

352

353 **Conclusion**

354 Our findings suggest that in patients with ischemic stroke, reduced eGFR but not
355 albuminuria was associated with cognitive impairment, measured by MMSE or MoCA.
356 The eGFR decline could be an effective indicator of cognitive impairment after a
357 stroke. These results suggest that the early stages of renal dysfunction could be an
358 effective target to prevent cognitive impairment in patients with stroke. It
359 emphasizes the need and possibility for early detection and early cognitive
360 impairment prevention after stroke.

361

362 **Acknowledgments**

363 None.

364

365 References

- 366 1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global
367 prevalence of dementia: a systematic review and metaanalysis. *Alzheimer's &*
368 *dementia : the journal of the Alzheimer's Association*. 2013 Jan;9(1):63-75.e2.
369 PubMed PMID: 23305823. Epub 2013/01/12. eng.
- 370 2. Plassman BL, Williams JW, Jr., Burke JR, Holsinger T, Benjamin S. Systematic
371 review: factors associated with risk for and possible prevention of cognitive decline in
372 later life. *Annals of internal medicine*. 2010 Aug 3;153(3):182-93. PubMed PMID:
373 20547887. Epub 2010/06/16. eng.
- 374 3. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al.
375 Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-
376 Analysis. *PloS one*. 2016;11(7):e0158765. PubMed PMID: 27383068. Pubmed Central
377 PMCID: Pmc4934905. Epub 2016/07/08. eng.
- 378 4. Deckers K, Camerino I, van Boxtel MP, Verhey FR, Irving K, Brayne C, et al.
379 Dementia risk in renal dysfunction: A systematic review and meta-analysis of
380 prospective studies. *Neurology*. 2017 Jan 10;88(2):198-208. PubMed PMID:
381 27974647. Pubmed Central PMCID: Pmc5224710. Epub 2016/12/16. eng.
- 382 5. Weiner DE, Gaussoin SA, Nord J, Auchus AP, Chelune GJ, Chonchol M, et al.
383 Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood
384 Pressure Intervention Trial (SPRINT). *American journal of kidney diseases : the*
385 *official journal of the National Kidney Foundation*. 2017 Sep;70(3):357-67. PubMed
386 PMID: 28606731. Pubmed Central PMCID: Pmc5572661. Epub 2017/06/14. eng.
- 387 6. Martens RJ, Kooman JP, Stehouwer CD, Dagnelie PC, van der Kallen CJ,
388 Koster A, et al. Estimated GFR, Albuminuria, and Cognitive Performance:
389 The Maastricht Study. *American journal of kidney diseases : the official journal of the*
390 *National Kidney Foundation*. 2017 Feb;69(2):179-91. PubMed PMID: 27291486. Epub
391 2016/06/14. eng.
- 392 7. Ekblad LL, Toppala S, Johansson JK, Koskinen S, Sundvall J, Rinne JO, et al.
393 Albuminuria and Microalbuminuria as Predictors of Cognitive Performance
394 in a General Population: An 11-Year Follow-Up Study. *Journal of Alzheimer's disease :*
395 *JAD*. 2018;62(2):635-48. PubMed PMID: 29480195. Epub 2018/02/27. eng.
- 396 8. Kong JY, Kim JS, Kang MH, Hwang HS, Won CW, Jeong KH. Renal
397 dysfunction is associated with decline of cognitive function in community-dwelling
398 older adults: Korean frailty and aging cohort study. 2020 Nov 10;20(1):462. PubMed
399 PMID: 33172388.
- 400 9. Etgen T, Chonchol M, Förstl H, Sander D. Chronic kidney disease and
401 cognitive impairment: a systematic review and meta-analysis. *American journal of*
402 *nephrology*. 2012;35(5):474-82. PubMed PMID: 22555151. Epub 2012/05/05. eng.
- 403 10. Kurella Tamura M, Yaffe K, Hsu CY, Yang J, Sozio S, Fischer M, et al.
404 Cognitive Impairment and Progression of CKD. *American journal of kidney diseases :*
405 *the official journal of the National Kidney Foundation*. 2016 Jul;68(1):77-83. PubMed
406 PMID: 26972681. Pubmed Central PMCID: Pmc4921255. Epub 2016/03/15. eng.
- 407 11. Joosten H, Izaks GJ, Slaets JP, de Jong PE, Visser ST, Bilo HJ, et al.
408 Association of cognitive function with albuminuria and eGFR in the general
409 population. *Clinical journal of the American Society of Nephrology : CJASN*. 2011
410 Jun;6(6):1400-9. PubMed PMID: 21566108. Pubmed Central PMCID: Pmc3109938.
411 Epub 2011/05/14. eng.
- 412 12. Barzilay JI, Younes N, Pop-Busui R, Florez H, Seaquist E, Falck-Ytter C, et al.
413 The cross-sectional association of renal dysfunction with tests of cognition in middle-
414 aged adults with early type 2 diabetes: The GRADE Study. *Journal of diabetes and its*

- 415 complications. 2021 Mar;35(3):107805. PubMed PMID: 33288412. Pubmed Central
416 PMCID: Pmc7870547. Epub 2020/12/09. eng.
- 417 13. Feng L, Yap KB, Yeoh LY, Ng TP. Kidney function and cognitive and functional
418 decline in elderly adults: findings from the Singapore longitudinal aging study.
419 Journal of the American Geriatrics Society. 2012 Jul;60(7):1208-14. PubMed PMID:
420 22702744. Epub 2012/06/19. eng.
- 421 14. Kono S, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, et al.
422 Impact of cystatin C and microalbuminuria on cognitive impairment in the population
423 of community-dwelling Japanese. *Atherosclerosis*. 2017 Oct;265:71-7. PubMed PMID:
424 28865325. Epub 2017/09/03. eng.
- 425 15. Lee S, Shimada H, Park H, Makizako H, Lee S, Doi T, et al. The association
426 between kidney function and cognitive decline in community-dwelling, elderly
427 Japanese people. *Journal of the American Medical Directors Association*. 2015
428 Apr;16(4):349.e1-5. PubMed PMID: 25669668. Epub 2015/02/12. eng.
- 429 16. Paterson EN, Maxwell AP, Kee F, Cruise S, Young IS, McGuinness B, et al.
430 Association of renal impairment with cognitive dysfunction in the Northern Ireland
431 Cohort for the Longitudinal Study of Ageing (NICOLA). 2021 Jul 23;36(8):1492-9.
432 PubMed PMID: 34038557.
- 433 17. Bai K, Pan Y, Lu F, Zhao Y, Wang J, Zhang L. Kidney function and cognitive
434 decline in an oldest-old Chinese population. *Clinical interventions in aging*.
435 2017;12:1049-54. PubMed PMID: 28740370. Pubmed Central PMCID: Pmc5505158.
436 Epub 2017/07/26. eng.
- 437 18. Palmer ND, Sink KM, Smith SC, Xu J, Bowden DW, Hugenschmidt CE, et al.
438 Kidney disease and cognitive function: African American-diabetes heart study MIND.
439 *American journal of nephrology*. 2014;40(3):200-7. PubMed PMID: 25323981.
440 Pubmed Central PMCID: Pmc4216628. Epub 2014/10/18. eng.
- 441 19. Berger I, Wu S, Masson P, Kelly PJ, Duthie FA, Whiteley W, et al. Cognition in
442 chronic kidney disease: a systematic review and meta-analysis. *BMC medicine*. 2016
443 Dec 14;14(1):206. PubMed PMID: 27964726. Pubmed Central PMCID: Pmc5155375.
444 Epub 2016/12/15. eng.
- 445 20. Helmer C, Stengel B, Metzger M, Froissart M, Massy ZA, Tzourio C, et al.
446 Chronic kidney disease, cognitive decline, and incident dementia: the 3C Study.
447 *Neurology*. 2011 Dec 6;77(23):2043-51. PubMed PMID: 22116945. Epub 2011/11/26.
448 eng.
- 449 21. Qu Y, Zhuo L, Li N, Hu Y, Chen W, Zhou Y, et al. Prevalence of post-stroke
450 cognitive impairment in china: a community-based, cross-sectional study. *PloS one*.
451 2015;10(4):e0122864. PubMed PMID: 25874998. Pubmed Central PMCID:
452 Pmc4395303. Epub 2015/04/16. eng.
- 453 22. De Ronchi D, Palmer K, Pioggiosi P, Atti AR, Berardi D, Ferrari B, et al. The
454 combined effect of age, education, and stroke on dementia and cognitive impairment
455 no dementia in the elderly. *Dementia and geriatric cognitive disorders*.
456 2007;24(4):266-73. PubMed PMID: 17700023. Epub 2007/08/19. eng.
- 457 23. Miwa K, Tanaka M, Okazaki S, Furukado S, Yagita Y, Sakaguchi M, et al.
458 Chronic kidney disease is associated with dementia independent of cerebral small-
459 vessel disease. *Neurology*. 2014 Mar 25;82(12):1051-7. PubMed PMID: 24553427.
460 Epub 2014/02/21. eng.
- 461 24. Kelly DM, Pendlebury ST. Associations of Chronic Kidney Disease With
462 Dementia Before and After TIA and Stroke: Population-Based Cohort Study. 2022
463 Feb 15;98(7):e711-e20. PubMed PMID: 34996878.
- 464 25. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al.
465 Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter

- 466 clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993
467 Jan;24(1):35-41. PubMed PMID: 7678184. Epub 1993/01/01. eng.
- 468 26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et
469 al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May
470 5;150(9):604-12. PubMed PMID: 19414839. Pubmed Central PMCID: Pmc2763564.
471 Epub 2009/05/06. eng.
- 472 27. Wang H, Liu T, Cai YY, Jiang H, Liu HX, Lin C. Kidney Function and Cognitive
473 Impairment in People Aged 80 Years and Over with Untreated Hypertension: A
474 Cross-Sectional Survey. Kidney & blood pressure research. 2016;41(1):70-7. PubMed
475 PMID: 26872346. Epub 2016/02/13. eng.
- 476 28. Wang F, Zhang L, Liu L, Wang H. Level of kidney function correlates with
477 cognitive decline. American journal of nephrology. 2010;32(2):117-21. PubMed PMID:
478 20714128. Epub 2010/08/18. eng.
- 479 29. Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, et al.
480 Kidney function and cognitive impairment in US adults: the Reasons for Geographic
481 and Racial Differences in Stroke (REGARDS) Study. American journal of kidney
482 diseases : the official journal of the National Kidney Foundation. 2008
483 Aug;52(2):227-34. PubMed PMID: 18585836. Pubmed Central PMCID: Pmc2593146.
484 Epub 2008/07/01. eng.
- 485 30. Kurella Tamura M, Xie D, Yaffe K, Cohen DL, Teal V, Kasner SE, et al.
486 Vascular risk factors and cognitive impairment in chronic kidney disease: the Chronic
487 Renal Insufficiency Cohort (CRIC) study. Clinical journal of the American Society of
488 Nephrology : CJASN. 2011 Feb;6(2):248-56. PubMed PMID: 20930087. Pubmed
489 Central PMCID: Pmc3052213. Epub 2010/10/12. eng.
- 490 31. Zhang J, Tang L, Hu J, Wang Y, Xu Y. Uric acid is associated with cognitive
491 impairment in the elderly patients receiving maintenance hemodialysis-A two-center
492 study. 2020 Mar;10(3):e01542. PubMed PMID: 31985179.
- 493 32. Viggiano D, Wagner CA, Martino G. Mechanisms of cognitive dysfunction in
494 CKD. 2020 Aug;16(8):452-69. PubMed PMID: 32235904.
- 495 33. Georgakis MK, Dimitriou NG, Karalexi MA, Mihas C, Nasothimiou EG,
496 Tousoulis D, et al. Albuminuria in Association with Cognitive Function and Dementia:
497 A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society.
498 2017 Jun;65(6):1190-8. PubMed PMID: 28152169. Epub 2017/02/06. eng.
- 499 34. Li H, Zhao S, Wang R, Gao B. The association between cognitive
500 impairment/dementia and albuminuria: a systematic review and meta-analysis.
501 Clinical and experimental nephrology. 2021 Aug 28. PubMed PMID: 34468878. Epub
502 2021/09/02. eng.
- 503 35. Takae K, Hata J, Ohara T, Yoshida D, Shibata M, Mukai N, et al. Albuminuria
504 Increases the Risks for Both Alzheimer Disease and Vascular Dementia in
505 Community-Dwelling Japanese Elderly: The Hisayama Study. Journal of the American
506 Heart Association. 2018 Jan 20;7(2). PubMed PMID: 29353232. Pubmed Central
507 PMCID: Pmc5850144. Epub 2018/01/22. eng.
- 508 36. Barzilay JI, Lovato JF, Murray AM, Williamson J, Ismail-Beigi F, Karl D, et al.
509 Albuminuria and cognitive decline in people with diabetes and normal renal function.
510 Clinical journal of the American Society of Nephrology : CJASN. 2013
511 Nov;8(11):1907-14. PubMed PMID: 23990163. Pubmed Central PMCID: Pmc3817915.
512 Epub 2013/08/31. eng.
- 513 37. Wei Y, Wei YK, Zhu J. Early markers of kidney dysfunction and cognitive
514 impairment among older adults. Journal of the neurological sciences. 2017 Apr
515 15;375:209-14. PubMed PMID: 28320132. Epub 2017/03/23. eng.
- 516 38. Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, et al.
517 Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies.

518 Archives of internal medicine. 2011 Jan 24;171(2):142-50. PubMed PMID: 21263104.
519 Epub 2011/01/26. eng.
520 39. Miller WG, Bruns DE, Hortin GL, Sandberg S, Aakre KM, McQueen MJ, et al.
521 Current issues in measurement and reporting of urinary albumin excretion. Clinical
522 chemistry. 2009 Jan;55(1):24-38. PubMed PMID: 19028824. Epub 2008/11/26. eng.
523 40. Fried L. Albuminuria and cognitive impairment. Clinical journal of the
524 American Society of Nephrology : CJASN. 2012 Mar;7(3):376-8. PubMed PMID:
525 22282483. Epub 2012/01/28. eng.
526 41. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology,
527 mechanisms and management. Annals of translational medicine. 2014 Aug;2(8):80.
528 PubMed PMID: 25333055. Pubmed Central PMCID: Pmc4200648. Epub 2014/10/22.
529 eng.

530

531

532

Table 1 Demographic and clinical characteristics of patients stratified by eGFR and UACR

	Overall n=608	Estimated glomerular filtration(ml/min/1.73 m ²)			<i>P</i> value	Urinary ACR (mg/g)			<i>P</i> value
		≥90	60-89	<60		<30	30-300	>300	
		n=371	n=207	n=30		n=338	n=240	n=30	
Age, y	66.6 ± 4.1	65.5 ± 3.5	68.0 ± 4.5	69.8 ± 4.5	<0.001	66.4 ± 4.2	66.8 ± 4.1	66.3 ± 3.7	0.45
Male, n(%)	316 (52.0)	192 (51.8)	105 (50.7)	19 (63.3)	0.43	186 (55.0)	115 (47.9)	15 (50.0)	0.235
BMI, ^a kg/m ²	25.0 ± 3.6	24.8 ± 3.4	24.9 ± 3.8	26.6 ± 4.0	0.033	24.6 ± 3.4	25.3 ± 3.7	25.9 ± 3.8	0.019
Education (> 6 years),n (%)	200 (32.9)	130 (35.0)	58 (28.0)	12 (40.0)	0.158	113 (33.4)	77 (32.1)	10 (33.3)	0.943
Systolic blood pressure on admission, mmHg	171.9 ± 20.2	170.0 ± 19.8	174.2 ± 20.7	178.9 ± 19.4	0.008	170.3 ± 18.4	173.8 ± 22.1	174.8 ± 23.3	0.079
Diastolic blood pressure on admission, mmHg	92.9 ± 12.2	92.1 ± 12.1	93.9 ± 12.4	96.5 ± 12.7	0.057	91.5 ± 11.7	94.6 ± 12.7	95.5 ± 12.8	0.006
Smoking, n (%)					0.112				0.057
Never	355 (58.5)	229 (61.7)	114 (55.3)	12 (40.0)		182 (54.0)	153 (63.7)	20 (66.7)	
Former	64 (10.5)	33 (8.9)	26 (12.6)	5 (16.7)		34 (10.1)	26 (10.8)	4 (13.3)	
Current	188 (31.0)	109 (29.4)	66 (32.0)	13 (43.3)		121 (35.9)	61 (25.4)	6 (20.0)	
Alcohol drinking, n (%)					0.474				0.18
Never	389 (64.0)	245 (66.0)	128 (61.8)	16 (53.3)		205 (60.7)	163 (67.9)	21 (70.0)	
Former	52 (8.6)	27 (7.3)	21 (10.1)	4 (13.3)		33 (9.8)	15 (6.2)	4 (13.3)	
Current	167 (27.5)	99 (26.7)	58 (28.0)	10 (33.3)		100 (29.6)	62 (25.8)	5 (16.7)	

Diabetes mellitus, ^b n (%)	50 (8.2)	34 (9.2)	13 (6.3)	3 (10.0)	0.45	21 (6.2)	23 (9.6)	6 (20.0)	0.019
Hypertension, n (%)	361 (59.4)	215 (58.0)	127 (61.4)	19 (63.3)	0.656	189 (55.9)	154 (64.2)	18 (60.0)	0.138
Stroke subtypes					0.149				0.911
Large artery	281 (46.2)	183 (49.3)	80 (38.6)	18 (60.0)		156 (46.2)	110 (45.8)	15 (50.0)	
Small vessel occlusion	309 (50.8)	176 (47.4)	121 (58.5)	12 (40.0)		171 (50.6)	124 (51.7)	14 (46.7)	
Cardioembolism	13 (2.1)	9 (2.4)	4 (1.9)	0 (0.0)		8 (2.4)	4 (1.7)	1 (3.3)	
Other determined etiology	3 (0.5)	1 (0.3)	2 (1.0)	0 (0.0)		1 (0.3)	2 (0.8)	0 (0.0)	
Undetermined etiology	2 (0.3)	2 (0.5)	0 (0.0)	0 (0.0)		2 (0.6)	0 (0.0)	0 (0.0)	
Laboratory results									
Total cholesterol, mmol/L	5.7 ± 1.2	5.6 ± 1.1	5.8 ± 1.3	5.8 ± 1.3	0.055	5.7 ± 1.2	5.7 ± 1.2	6.0 ± 1.1	0.423
Triglyceride, mmol/L	1.6 ± 0.9	1.7 ± 1.1	1.5 ± 0.7	1.6 ± 0.7	0.036	1.5 ± 0.8	1.8 ± 1.1	1.6 ± 0.5	0.016
Homocysteine, umol/L	16.1 ± 9.4	14.7 ± 7.9	17.0 ± 8.6	27.9 ± 18.7	<0.001	15.5 ± 7.1	17.0 ± 11.7	17.1 ± 10.2	0.124
Uric Acid, mmol/L	298.6 ± 75.4	284.5 ± 68.9	312.3 ± 75.2	377.7 ± 89.6	<0.001	299.0 ± 71.8	296.2 ± 79.5	313.0 ± 81.9	0.511
Fasting glucose, mmol/L	6.1 ± 1.8	6.2 ± 2.0	6.1 ± 1.6	6.3 ± 1.4	0.698	6.0 ± 1.7	6.2 ± 1.9	6.7 ± 2.5	0.082
Estimated glomerular filtration rate, mL/min/1.73m ²	88.4 ± 12.9	96.0 ± 5.3	79.8 ± 8.5	53.2 ± 8.2	<0.001	89.0 ± 11.9	88.3 ± 13.0	81.8 ± 19.8	0.013
Log10 Urinary ACR	1.5 ± 0.5	1.5 ± 0.5	1.5 ± 0.4	1.7 ± 0.7	0.246	1.2 ± 0.2	1.8 ± 0.3	2.8 ± 0.3	<0.001
Neural function assessment, mean (SD)									
MMSE score, mean ± SD (range 0–30)	21.4 ± 2.1	22.0 ± 1.9	21.1 ± 1.6	17.5 ± 2.8	<0.001	21.5 ± 2.0	21.4 ± 2.1	20.8 ± 2.9	0.18

MoCA score, mean ± SD (range 0–30)	17.9 ± 2.3	18.7 ± 2.0	17.2 ± 1.9	13.4 ± 2.6	<0.001	18.0 ± 2.3	17.9 ± 2.3	17.2 ± 2.8	0.18
NIHSS score, mean ± SD (range 0–24)	5.0 ± 2.2	5.1 ± 2.3	4.8 ± 2.1	5.6 ± 1.8	0.091	5.1 ± 2.2	4.8 ± 2.1	5.3 ± 2.8	0.302

Abbreviations: BMI, body mass index. UACR: urine albumin-creatinine ratio

Values are presented as mean ± SD for continuous variables and n (%) for categorical variables.

^aBMI was calculated as weight in kilograms divided by height in meters squared.

^bDiabetes mellitus was defined as self-reported physician diagnosed diabetes.

^cHypertension was defined as self-reported physician diagnosed hypertension.

Table 2 Linear regression analysis of the association between levels of eGFR and albuminuria measured by UACR and cognitive performance

Variables	No. of patients (%)	MMSE				MoCA			
		Crude		adjusted*		Crude		adjusted*	
		β (95%CI)	<i>P</i>	β (95%CI)	<i>P</i>	β (95%CI)	<i>P</i>	β (95%CI)	<i>P</i>
eGFR, (ml/min/1.73m ²) categories									
≥90	371(61)	0		0		0		0	
60-90	207(34)	-0.9 (-1.2, -0.6)	<0.001	-0.7 (-1.0, -0.3)	<0.001	-1.5 (-1.8, -1.2)	<0.001	-1.4 (-1.7, -1.0)	<0.001
<60	30(5)	-4.4 (-5.1, -3.8)	<0.001	-4.2 (-5.0, -3.4)	<0.001	-5.3 (-6.0, -4.5)	<0.001	-5.2 (-6.1, -4.4)	<0.001
eGFR per 5-unit decline	608(100)	-0.4 (-0.5, -0.4)	<0.001	-0.4 (-0.5, -0.4)	<0.001	-0.5 (-0.6, -0.5)	<0.001	-0.6 (-0.7, -0.5)	<0.001
UACR(mg/g) categories									
<30	338(56)	0		0		0		0	
30-300	240(39)	-0.1 (-0.4, 0.3)	0.716	0.0 (-0.3, 0.3)	0.971	-0.0 (-0.4, 0.3)	0.858	0.0 (-0.3, 0.3)	0.826
≥300	30(5)	-0.7 (-1.5, 0.0)	0.064	-0.3 (-1.0, 0.4)	0.387	-0.8 (-1.7, 0.0)	0.065	-0.2 (-0.9, 0.6)	0.68
log-UACR	608(100)	-0.2 (-0.6, 0.2)	0.262	-0.0 (-0.4, 0.3)	0.784	-0.3 (-0.6, 0.1)	0.214	-0.0 (-0.4, 0.3)	0.834

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

*Adjusted for age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either baseline estimated glomerular filtration rate or UACR.

Table 3 Multivariable adjusted* Linear regression of MMSE scores with UACR and eGFR within subgroups

Subgroups	Comparing UACR (30-300, >300 vs <30mg/g)			P for interaction	Comparing eGFR (60-90, <60 vs ≥90 ml/min/1.73m2)			P for interaction
	<30	30-300	>300		≥90	60-90	<60	
	β (95%CI) P				β (95%CI) P			
Gender				0.050				0.123
Male	0	0.3 (-0.1, 0.7) 0.137	-0.5 (-1.5, 0.4) 0.278		0	-1.0 (-1.5, -0.5) <0.001	-4.1 (-5.2, -3.1) <0.001	
Female	0	-0.4 (-0.8, 0.1) 0.104	-0.2 (-1.2, 0.8) 0.703		0	-0.5 (-1.0, -0.0) 0.050	-4.4 (-5.7, -3.1) <0.001	
Age dichotomous				0.588				0.609
Lower	0	-0.0 (-0.5, 0.4) 0.842	-0.7 (-1.7, 0.4) 0.215		0	-0.8 (-1.3, -0.3) 0.002	-5.8 (-7.4, -4.3) <0.001	
Higher	0	0.1 (-0.4, 0.5) 0.717	0.3 (-0.7, 1.3) 0.503		0	-0.8 (-1.2, -0.4) <0.001	-3.9 (-4.6, -3.1) <0.001	
Systolic blood pressure dichotomous				0.657				0.149
Lower	0	-0.1 (-0.5, 0.4) 0.781	-0.2 (-1.3, 0.9) 0.740		0	-0.6 (-1.2, -0.1) 0.021	-2.8 (-4.2, -1.4) <0.001	
Higher	0	0.1 (-0.3, 0.5) 0.652	-0.3 (-1.2, 0.7) 0.562		0	-0.7 (-1.2, -0.2) 0.005	-4.2 (-5.1, -3.3) <0.001	
NIHSS score dichotomous				0.375				0.953
Lower	0	-0.2 (-0.7, 0.3) 0.393	-0.6 (-1.7, 0.5) 0.304		0	-0.6 (-1.1, -0.0) 0.035	-3.7 (-5.4, -2.0) <0.001	
Higher	0	0.1 (-0.3, 0.5) 0.767	-0.0 (-0.9, 0.9) 0.982		0	-0.7 (-1.1, -0.2) 0.006	-4.2 (-5.1, -3.3) <0.001	
Stroke subtypes				0.311				0.122
Large artery	0	0.1 (-0.4, 0.6) 0.661	0.3 (-0.7, 1.3) 0.531		0	-0.8 (-1.4, -0.2) 0.006	-4.3 (-5.3, -3.2) <0.001	
Small vessel occlusion	0	-0.2 (-0.6, 0.2) 0.330	-0.4 (-1.4, 0.6) 0.441		0	-0.5 (-1.0, -0.1) 0.026	-4.0 (-5.3, -2.8) <0.001	
Blood glucose dichotomous				0.849				0.372
Lower	0	-0.3 (-0.9, 0.2) 0.225	-2.5 (-5.2, 0.1) 0.059		0	-1.0 (-1.5, -0.5) <0.001	-4.5 (-5.7, -3.4) <0.001	

Higher	0	0.1 (-0.4, 0.6) 0.768	-0.0 (-1.4, 1.3) 0.951	0	-0.5 (-1.0, 0.0) 0.065	-3.9 (-5.1, -2.8) <0.001
--------	---	-----------------------	------------------------	---	------------------------	--------------------------

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

*Adjusted, if not stratified, age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either estimated glomerular filtration rate or UACR.

Table 4 Multivariable adjusted* Linear regression of MoCA scores with UACR and eGFR within subgroups

Subgroups	Comparing UACR (30-300, >300 vs <30mg/g)			P for interaction	Comparing eGFR (60-90, <60 vs ≥90 ml/min/1.73m ²)			P for interaction
	<30	30-300	>300		≥90	60-90	<60	
	β (95%CI) P				β (95%CI) P			
Gender				0.107				0.195
Male	0	0.3 (-0.1, 0.8) 0.149	-0.1 (-1.1, 1.0) 0.910		0	-1.7 (-2.2, -1.1) <0.001	-5.4 (-6.5, -4.3) <0.001	
Female	0	-0.3 (-0.8, 0.2) 0.197	-0.2 (-1.3, 0.8) 0.673		0	-1.1 (-1.7, -0.6) <0.001	-4.8 (-6.2, -3.3) <0.001	
Age dichotomous				0.352				0.341
Lower	0	0.1 (-0.4, 0.6) 0.658	-0.6 (-1.7, 0.6) 0.345		0	-1.3 (-1.9, -0.7) <0.001	-6.1 (-8.0, -4.3) <0.001	
Higher	0	0.1 (-0.4, 0.5) 0.819	0.4 (-0.6, 1.4) 0.411		0	-1.4 (-1.9, -0.9) <0.001	-5.1 (-6.1, -4.1) <0.001	
Systolic blood pressure dichotomous				0.595				0.402
Lower	0	0.0 (-0.5, 0.5) 0.922	0.1 (-1.0, 1.3) 0.825		0	-1.2 (-1.8, -0.7) <0.001	-4.2 (-5.6, -2.7) <0.001	
Higher	0	0.0 (-0.4, 0.4) 0.969	-0.3 (-1.3, 0.7) 0.533		0	-1.4 (-1.9, -0.9) <0.001	-5.7 (-6.8, -4.6) <0.001	
NIHSS score dichotomous				0.422				0.835
Lower	0	-0.3 (-0.8, 0.3) 0.318	-0.1 (-1.2, 1.1) 0.932		0	-1.3 (-1.9, -0.7) <0.001	-5.1 (-7.0, -3.3) <0.001	
Higher	0	-0.1 (-1.2, 1.1) 0.932	-0.1 (-1.0, 0.9) 0.879		0	-1.4 (-1.9, -0.9) <0.001	-5.3 (-6.3, -4.4) <0.001	
Stroke subtypes				0.391				0.576
Large artery	0	0.3 (-0.2, 0.7) 0.277	0.2 (-0.8, 1.3) 0.653		0	-1.4 (-2.0, -0.8) <0.001	-4.9 (-6.0, -3.8) <0.001	
Small vessel occlusion	0	-0.2 (-0.7, 0.2) 0.310	0.1 (-1.0, 1.2) 0.825		0	-1.3 (-1.8, -0.8) <0.001	-5.7 (-7.1, -4.2) <0.001	
Blood glucose dichotomous				0.409				0.585
Lower	0	0.0 (-0.4, 0.5) 0.960	-0.5 (-1.5, 0.5) 0.303		0	-1.7 (-2.3, -1.1) <0.001	-5.3 (-6.6, -4.0) <0.001	
Higher	0	-0.0 (-0.5, 0.4) 0.838	-0.1 (-1.1, 1.0) 0.918		0	-1.1 (-1.7, -0.6) <0.001	-5.1 (-6.3, -3.9) <0.001	

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR: urine albumin-creatinine ratio

*Adjusted, if not stratified, age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure and either estimated glomerular filtration rate or UACR.

Table 5 Association of joint UACR and eGFR stratum with cognitive performance (β 95% CI)

eGFR, (ml/min/1.73m ²)		MMSE		MoCA	
		UACR(mg/g) categories		UACR(mg/g) categories	
		<30	≥30	<30	≥30
≥90	Crude	0.00	0.0 (-0.4, 0.4)	0.00	0.2 (-0.3, 0.6)
	Adjusted*	0.00	-0.0 (-0.4, 0.4)	0.00	0.1 (-0.3, 0.6)
<90	Crude	-1.2 (-1.7, -0.8)	-1.5 (-2.0, -1.0)	-1.7 (-2.2, -1.3)	-2.1 (-2.6, -1.6)
	Adjusted*	-0.8 (-1.3, -0.4)	-1.0 (-1.5, -0.5)	-1.4 (-1.9, -0.9)	-1.7 (-2.3, -1.2)

Abbreviations: CI: confidence interval; eGFR: estimated glomerular filtration rate; UACR, urine albumin-creatinine ratio.

* adjusted for age, gender, BMI, education, diabetes and hypertension history, NIHSS score, stroke subtypes, smoking and alcohol drinking status, serum total cholesterol, triglyceride, uric acid, homocysteine, fasting glucose, systolic blood pressure.